Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years

Results of the AIDA-2000 trial of the GIMEMA Group

Francesco Lo-Coco, Giuseppe Avvisati, Marco Vignetti, Massimo Breccia, Eugenio Gallo, Alessandro Rambaldi, Francesca Paoloni, Giuseppe Fioritoni, Felicetto Ferrara, Giorgina Specchia, Giuseppe Cimino, Daniela Diverio, Erika Borlenghi, Giovanni Martinelli, Francesco Di Raimondo, Eros Di Bona, Paola Fazi, Antonio Peta, Alberto Bosi, Angelo M. Carella & 5 others Francesco Fabbiano, Enrico M. Pogliani, Maria C. Petti, Sergio Amadori, Franco Mandelli

Research output: Contribution to journalArticle

177 Citations (Scopus)

Abstract

After the identification of discrete relapse-risk categories in patients with acute promyelocytic leukemia (APL) receiving alltrans retinoic and idarubicin (AIDA)-like therapies, the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) designed a protocol for newly diagnosed APL (AIDA-2000) in which postremission treatment was risk-adapted. Patients with low/intermediate risk received remission at 3 anthracycline-based consolidation courses, whereas high-risk patients received the same schedule as in the previous, non-risk-adapted AIDA-0493 trial including cytarabine.In addition, all patients in the AIDA-2000 received all-trans retinoic acid (ATRA) for 15 days during each consolidation. After induction, 600 of 636 (94.3%) and 420 of 445 (94.4%) patients achieved complete remission in the AIDA-0493 and AIDA-2000, respectively. The 6-year overall survival and cumulative incidence of relapse (CIR) rates were 78.1% versus 87.4% (P = .001) and 27.7% versus 10.7% (P <.0001). Significantly lower CIR rates for patients in the AIDA-2000 were most evident in the high-risk group (49.7% vs 9.3%, respectively, P <.0001). Our data confirm that anthracycline-based consolidation is at least equally effective as cytarabine-containing regimens for low-/intermediate-risk patients and suggest that a risk-adapted strategy including ATRA for consolidation improves outcome in newly diagnosed APL. Furthermore, our results highlight the role of cytarabine coupled to anthracyclines and ATRA during consolidation in the high-risk group. This trial was registered at www.clinicaltrials.gov as #NCT 001064570.

Original languageEnglish
Pages (from-to)3171-3179
Number of pages9
JournalBlood
Volume116
Issue number17
DOIs
Publication statusPublished - Oct 28 2010

Fingerprint

Idarubicin
Acute Promyelocytic Leukemia
Consolidation
Young Adult
Anthracyclines
Cytarabine
Tretinoin
Therapeutics
Recurrence
Incidence
Appointments and Schedules
Survival

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years : Results of the AIDA-2000 trial of the GIMEMA Group. / Lo-Coco, Francesco; Avvisati, Giuseppe; Vignetti, Marco; Breccia, Massimo; Gallo, Eugenio; Rambaldi, Alessandro; Paoloni, Francesca; Fioritoni, Giuseppe; Ferrara, Felicetto; Specchia, Giorgina; Cimino, Giuseppe; Diverio, Daniela; Borlenghi, Erika; Martinelli, Giovanni; Di Raimondo, Francesco; Di Bona, Eros; Fazi, Paola; Peta, Antonio; Bosi, Alberto; Carella, Angelo M.; Fabbiano, Francesco; Pogliani, Enrico M.; Petti, Maria C.; Amadori, Sergio; Mandelli, Franco.

In: Blood, Vol. 116, No. 17, 28.10.2010, p. 3171-3179.

Research output: Contribution to journalArticle

Lo-Coco, F, Avvisati, G, Vignetti, M, Breccia, M, Gallo, E, Rambaldi, A, Paoloni, F, Fioritoni, G, Ferrara, F, Specchia, G, Cimino, G, Diverio, D, Borlenghi, E, Martinelli, G, Di Raimondo, F, Di Bona, E, Fazi, P, Peta, A, Bosi, A, Carella, AM, Fabbiano, F, Pogliani, EM, Petti, MC, Amadori, S & Mandelli, F 2010, 'Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA Group', Blood, vol. 116, no. 17, pp. 3171-3179. https://doi.org/10.1182/blood-2010-03-276196
Lo-Coco, Francesco ; Avvisati, Giuseppe ; Vignetti, Marco ; Breccia, Massimo ; Gallo, Eugenio ; Rambaldi, Alessandro ; Paoloni, Francesca ; Fioritoni, Giuseppe ; Ferrara, Felicetto ; Specchia, Giorgina ; Cimino, Giuseppe ; Diverio, Daniela ; Borlenghi, Erika ; Martinelli, Giovanni ; Di Raimondo, Francesco ; Di Bona, Eros ; Fazi, Paola ; Peta, Antonio ; Bosi, Alberto ; Carella, Angelo M. ; Fabbiano, Francesco ; Pogliani, Enrico M. ; Petti, Maria C. ; Amadori, Sergio ; Mandelli, Franco. / Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years : Results of the AIDA-2000 trial of the GIMEMA Group. In: Blood. 2010 ; Vol. 116, No. 17. pp. 3171-3179.
@article{0665a4f8eae94abfbb623993809b78bb,
title = "Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA Group",
abstract = "After the identification of discrete relapse-risk categories in patients with acute promyelocytic leukemia (APL) receiving alltrans retinoic and idarubicin (AIDA)-like therapies, the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) designed a protocol for newly diagnosed APL (AIDA-2000) in which postremission treatment was risk-adapted. Patients with low/intermediate risk received remission at 3 anthracycline-based consolidation courses, whereas high-risk patients received the same schedule as in the previous, non-risk-adapted AIDA-0493 trial including cytarabine.In addition, all patients in the AIDA-2000 received all-trans retinoic acid (ATRA) for 15 days during each consolidation. After induction, 600 of 636 (94.3{\%}) and 420 of 445 (94.4{\%}) patients achieved complete remission in the AIDA-0493 and AIDA-2000, respectively. The 6-year overall survival and cumulative incidence of relapse (CIR) rates were 78.1{\%} versus 87.4{\%} (P = .001) and 27.7{\%} versus 10.7{\%} (P <.0001). Significantly lower CIR rates for patients in the AIDA-2000 were most evident in the high-risk group (49.7{\%} vs 9.3{\%}, respectively, P <.0001). Our data confirm that anthracycline-based consolidation is at least equally effective as cytarabine-containing regimens for low-/intermediate-risk patients and suggest that a risk-adapted strategy including ATRA for consolidation improves outcome in newly diagnosed APL. Furthermore, our results highlight the role of cytarabine coupled to anthracyclines and ATRA during consolidation in the high-risk group. This trial was registered at www.clinicaltrials.gov as #NCT 001064570.",
author = "Francesco Lo-Coco and Giuseppe Avvisati and Marco Vignetti and Massimo Breccia and Eugenio Gallo and Alessandro Rambaldi and Francesca Paoloni and Giuseppe Fioritoni and Felicetto Ferrara and Giorgina Specchia and Giuseppe Cimino and Daniela Diverio and Erika Borlenghi and Giovanni Martinelli and {Di Raimondo}, Francesco and {Di Bona}, Eros and Paola Fazi and Antonio Peta and Alberto Bosi and Carella, {Angelo M.} and Francesco Fabbiano and Pogliani, {Enrico M.} and Petti, {Maria C.} and Sergio Amadori and Franco Mandelli",
year = "2010",
month = "10",
day = "28",
doi = "10.1182/blood-2010-03-276196",
language = "English",
volume = "116",
pages = "3171--3179",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "17",

}

TY - JOUR

T1 - Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years

T2 - Results of the AIDA-2000 trial of the GIMEMA Group

AU - Lo-Coco, Francesco

AU - Avvisati, Giuseppe

AU - Vignetti, Marco

AU - Breccia, Massimo

AU - Gallo, Eugenio

AU - Rambaldi, Alessandro

AU - Paoloni, Francesca

AU - Fioritoni, Giuseppe

AU - Ferrara, Felicetto

AU - Specchia, Giorgina

AU - Cimino, Giuseppe

AU - Diverio, Daniela

AU - Borlenghi, Erika

AU - Martinelli, Giovanni

AU - Di Raimondo, Francesco

AU - Di Bona, Eros

AU - Fazi, Paola

AU - Peta, Antonio

AU - Bosi, Alberto

AU - Carella, Angelo M.

AU - Fabbiano, Francesco

AU - Pogliani, Enrico M.

AU - Petti, Maria C.

AU - Amadori, Sergio

AU - Mandelli, Franco

PY - 2010/10/28

Y1 - 2010/10/28

N2 - After the identification of discrete relapse-risk categories in patients with acute promyelocytic leukemia (APL) receiving alltrans retinoic and idarubicin (AIDA)-like therapies, the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) designed a protocol for newly diagnosed APL (AIDA-2000) in which postremission treatment was risk-adapted. Patients with low/intermediate risk received remission at 3 anthracycline-based consolidation courses, whereas high-risk patients received the same schedule as in the previous, non-risk-adapted AIDA-0493 trial including cytarabine.In addition, all patients in the AIDA-2000 received all-trans retinoic acid (ATRA) for 15 days during each consolidation. After induction, 600 of 636 (94.3%) and 420 of 445 (94.4%) patients achieved complete remission in the AIDA-0493 and AIDA-2000, respectively. The 6-year overall survival and cumulative incidence of relapse (CIR) rates were 78.1% versus 87.4% (P = .001) and 27.7% versus 10.7% (P <.0001). Significantly lower CIR rates for patients in the AIDA-2000 were most evident in the high-risk group (49.7% vs 9.3%, respectively, P <.0001). Our data confirm that anthracycline-based consolidation is at least equally effective as cytarabine-containing regimens for low-/intermediate-risk patients and suggest that a risk-adapted strategy including ATRA for consolidation improves outcome in newly diagnosed APL. Furthermore, our results highlight the role of cytarabine coupled to anthracyclines and ATRA during consolidation in the high-risk group. This trial was registered at www.clinicaltrials.gov as #NCT 001064570.

AB - After the identification of discrete relapse-risk categories in patients with acute promyelocytic leukemia (APL) receiving alltrans retinoic and idarubicin (AIDA)-like therapies, the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) designed a protocol for newly diagnosed APL (AIDA-2000) in which postremission treatment was risk-adapted. Patients with low/intermediate risk received remission at 3 anthracycline-based consolidation courses, whereas high-risk patients received the same schedule as in the previous, non-risk-adapted AIDA-0493 trial including cytarabine.In addition, all patients in the AIDA-2000 received all-trans retinoic acid (ATRA) for 15 days during each consolidation. After induction, 600 of 636 (94.3%) and 420 of 445 (94.4%) patients achieved complete remission in the AIDA-0493 and AIDA-2000, respectively. The 6-year overall survival and cumulative incidence of relapse (CIR) rates were 78.1% versus 87.4% (P = .001) and 27.7% versus 10.7% (P <.0001). Significantly lower CIR rates for patients in the AIDA-2000 were most evident in the high-risk group (49.7% vs 9.3%, respectively, P <.0001). Our data confirm that anthracycline-based consolidation is at least equally effective as cytarabine-containing regimens for low-/intermediate-risk patients and suggest that a risk-adapted strategy including ATRA for consolidation improves outcome in newly diagnosed APL. Furthermore, our results highlight the role of cytarabine coupled to anthracyclines and ATRA during consolidation in the high-risk group. This trial was registered at www.clinicaltrials.gov as #NCT 001064570.

UR - http://www.scopus.com/inward/record.url?scp=77958499078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958499078&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-03-276196

DO - 10.1182/blood-2010-03-276196

M3 - Article

VL - 116

SP - 3171

EP - 3179

JO - Blood

JF - Blood

SN - 0006-4971

IS - 17

ER -